Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20527174 | 0.91 | SMN1; SMN2 (0.50) | ATRALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL21451867 | 0.87 | SCN3A (0.42) | P2RY12PRKDC | |
| SCHEMBL20527216 | 0.83 | P2RY12 (0.46) | P2RY12ALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL16693605 | 0.79 | SMN1; SMN2 (0.43) | ATRALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL2184236 | 0.77 | WNT3A (0.55) | — | |
| SCHEMBL21451631 | 0.77 | NAMPT (0.47) | LMNASMN1; SMN2NPC1USP2TSHR | |
| SCHEMBL2028022 | 0.76 | PRKDC (0.43) | P2RY12LMNAMAPTPRKDC | |
| SCHEMBL14509989 | 0.75 | MEN1 (0.49) | P2RY12ALDH1A1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL20527300 | 0.74 | P2RY12 (0.40) | P2RY12LMNAKDM4ERAB9AMAPT | |
| SCHEMBL16693604 | 0.73 | RAB9A (0.50) | LMNASMN1; SMN2NPC1USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2024-02-27 | — | — | US | disclosed |
| US-20230302142-A1 | Cytotoxic Agents | Pheon Therapeutics Ltd. (GB) | 2023-09-28 | — | — | US | disclosed |
| EP-4188927-A1 | CYTOTOXIC AGENTS | Pheon Therapeutics Ltd (GB) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022023735-A1 | CYTOTOXIC AGENTS | FEMTOGENIX LIMITED (GB) | 2022-02-03 | — | — | WO | disclosed |
| US-20210206763-A1 | Anti-Proliferative Agents | PHEON THERAPEUTICS LTD (GB) | 2021-07-08 | — | — | US | disclosed |
| US-10975072-B2 | Substituted 6a,7,8,9,10,12-hexahydrobenzo[e]pyrido[1,2-a][1,4]diazepines as anti-proliferative agents | FEMTOGENIX LIMITED | 2021-04-13 | — | — | US | disclosed |
| US-10975074-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | FEMTOGENIX LIMITED | 2021-04-13 | — | — | US | disclosed |
| US-20190308970-A1 | ANTI-LIFERATIVE AGENTS COMPRISING SUBSTITUTED PYRROLO-, INDOLINO- OR TETRAHYDROISOQUINOLINE-BENZODIAZEPINES | PHEON THERAPEUTICS LTD (GB) | 2019-10-10 | — | — | US | disclosed |
| US-20180339985-A1 | PDD COMPOUNDS | FEMTOGENIX LIMITED (GB) | 2018-11-29 | — | — | US | disclosed |
| US-20180291021-A1 | PDD COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2018-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206763-A1 | Anti-Proliferative Agents | CCND2, BRD2, DRD2 | P2RY12 1682/4885ATR 2973/4885ALDH1A1 3187/4885 |
| US-10975074-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | CNR1, GABRA1, BAK1 | P2RY12 1595/4885ATR 1522/4885ALDH1A1 163/4885 |
| US-10975072-B2 | Substituted 6a,7,8,9,10,12-hexahydrobenzo[e]pyrido[1,2-a][1,4]diazepines as anti-proliferative agents | PDCD1, CCND1, PDCD6 | P2RY12 878/4885ATR 3396/4885ALDH1A1 50/4885 |
| US-20190308970-A1 | ANTI-LIFERATIVE AGENTS COMPRISING SUBSTITUTED PYRROLO-, INDOLINO- OR TETRAHYDROISOQUINOLINE-BENZODIAZEPINES | GABRA1, GABBR1, GABRA2 | P2RY12 2542/4885ATR 791/4885ALDH1A1 364/4885 |
| US-20180291021-A1 | PDD COMPOUNDS | DRD1, DRD3, DRD2 | P2RY12 1823/4885ATR 3162/4885ALDH1A1 3010/4885 |
| US-20230302142-A1 | Cytotoxic Agents | ANXA11, ANXA5, HAX1 | P2RY12 1787/4885ATR 1948/4885ALDH1A1 3438/4885 |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | MKI67, CCND2, CCND1 | P2RY12 1752/4885ATR 1760/4885ALDH1A1 443/4885 |
| US-20180339985-A1 | PDD COMPOUNDS | DRD1, DRD3, DRD2 | P2RY12 2267/4885ATR 3433/4885ALDH1A1 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.